Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel.2011 · 113 citations
2. 2“Very Compelling” Results for ADC in TNBC Trial2021 · 5 citations
3. 3Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study2019 · 365 citations
4. 4Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer2017 · 410 citations
5. 5Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer2021 · 1,556 citations